Profile Previews

Get a glimpse into our company and investor data—powered by the PitchBook Platform

Sigma-Tau Pharmaceuticals (US Marketing Rights to Defribotide)

M&A STATUS
Asset Purch. LATEST DEAL TYPE
1 FINANCING ROUNDS
Description

A drug used for the treatment of hepatic veno-occlusive disease. The asset is used for the treatment of severe hepatic veno-occlusive disease which is an early complication in patients undertaking hematopoietic stem cell transplantation therapy.

Ownership Status
Acquired/Merged
Financing Status
Corporate Backed or Acquired
Primary Industry
Other Devices and Supplies
Other Industries
Pharmaceuticals
Other Pharmaceuticals and Biotechnology
Primary Office
  • United States

Sigma-Tau Pharmaceuticals (US Marketing Rights to Defribotide) Valuation and Funding

Deal Type Date Amount Post-Val Valuation/
EBITDA
Debt Status

This information is reserved for PitchBook Platform users. To explore Sigma-Tau Pharmaceuticals (US Marketing Rights to Defribotide)‘s full profile, request access.

Request full access to PitchBook

Sigma-Tau Pharmaceuticals (US Marketing Rights to Defribotide) Former Investors

Investor Name Investor Type Holding Participating Rounds Investor Since Board Seat Contact Info

This information is reserved for PitchBook Platform users. To explore Sigma-Tau Pharmaceuticals (US Marketing Rights to Defribotide)‘s full profile, request access.

Request full access to PitchBook